ES2330362T3 - Proteinas de union a gag. - Google Patents

Proteinas de union a gag. Download PDF

Info

Publication number
ES2330362T3
ES2330362T3 ES06117339T ES06117339T ES2330362T3 ES 2330362 T3 ES2330362 T3 ES 2330362T3 ES 06117339 T ES06117339 T ES 06117339T ES 06117339 T ES06117339 T ES 06117339T ES 2330362 T3 ES2330362 T3 ES 2330362T3
Authority
ES
Spain
Prior art keywords
protein
modified
gag
binding
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06117339T
Other languages
English (en)
Spanish (es)
Inventor
Andreas J. Kungl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protaffin Biotechnologie AG
Original Assignee
Protaffin Biotechnologie AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protaffin Biotechnologie AG filed Critical Protaffin Biotechnologie AG
Application granted granted Critical
Publication of ES2330362T3 publication Critical patent/ES2330362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5421IL-8
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES06117339T 2003-12-04 2004-12-02 Proteinas de union a gag. Expired - Lifetime ES2330362T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1952/2003 2003-12-04
AT0195203A AT412785B (de) 2003-12-04 2003-12-04 Gag-bindungsproteine

Publications (1)

Publication Number Publication Date
ES2330362T3 true ES2330362T3 (es) 2009-12-09

Family

ID=33494536

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06117339T Expired - Lifetime ES2330362T3 (es) 2003-12-04 2004-12-02 Proteinas de union a gag.
ES04801190T Expired - Lifetime ES2369139T3 (es) 2003-12-04 2004-12-02 Proteinas de unión a gag.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04801190T Expired - Lifetime ES2369139T3 (es) 2003-12-04 2004-12-02 Proteinas de unión a gag.

Country Status (20)

Country Link
US (4) US7585937B2 (enExample)
EP (5) EP2311866A1 (enExample)
JP (3) JP4980721B2 (enExample)
KR (2) KR101188785B1 (enExample)
CN (1) CN1890264B (enExample)
AT (3) AT412785B (enExample)
AU (1) AU2004295104B2 (enExample)
BR (1) BRPI0416544A (enExample)
CA (1) CA2546789A1 (enExample)
CY (2) CY1109480T1 (enExample)
DE (1) DE602004022595D1 (enExample)
DK (2) DK1689775T3 (enExample)
ES (2) ES2330362T3 (enExample)
IL (1) IL175565A0 (enExample)
NZ (1) NZ547612A (enExample)
PL (2) PL1752470T3 (enExample)
PT (2) PT1752470E (enExample)
SG (1) SG149000A1 (enExample)
SI (2) SI1689775T1 (enExample)
WO (1) WO2005054285A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine
AU2006291990B2 (en) 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CN100366637C (zh) * 2005-11-17 2008-02-06 中国人民解放军第四军医大学 人白细胞介素8拮抗蛋白及其制备方法
US9422356B2 (en) * 2006-01-31 2016-08-23 Republic Of Korea (Republic Of National Fisheries Research And Development Institute) Artificial signal peptide for expressing an insoluble protein as a soluble active form
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP1894571A1 (en) * 2006-08-29 2008-03-05 Protaffin Biotechnologie AG Use of modified interleukin-8 proteins for treating reperfusion injury or transplant rejection
US20100075918A1 (en) * 2006-12-08 2010-03-25 Lokeshwar Vinata B Hyaluronidase inhibitors as anti-cancer agents
AT504685B1 (de) * 2006-12-20 2009-01-15 Protaffin Biotechnologie Ag Fusionsproteine
WO2009023047A2 (en) * 2007-05-07 2009-02-19 Peptimmune, Inc. Methods for the directed expansion of epitopes for use as antibody ligands
EP2042516A1 (en) * 2007-09-27 2009-04-01 Protaffin Biotechnologie AG Glycosaminoglycan-antagonising MCP-1 mutants and methods of using same
EP2185719B1 (en) * 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
EP2053060A1 (en) 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
US8314212B2 (en) 2008-02-08 2012-11-20 Lindsey Miles Plasminogen receptor PLG-RKT and antibodies thereof
JP2012516143A (ja) 2009-01-30 2012-07-19 プロットアフィン ビオテヒノロギー アクチエンゲゼルシャフト グリコサミノグリカンを拮抗するmcp−1突然変異体およびその使用方法
AU2010294225A1 (en) 2009-09-11 2012-04-05 Protaffin Biotechnologie Ag Composition for treatment of CXCL8-mediated lung inflammation
CA2776513C (en) 2009-11-24 2017-08-01 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
US20140073557A1 (en) 2011-03-16 2014-03-13 Protaffin Biotechnologie Ag Fgfri-based antagonists with improved glycosaminoglycan affinity and methods of using same
EP2729487A2 (en) 2011-07-08 2014-05-14 Protaffin Biotechnologie AG Novel sdf-1-based glycosaminoglycan antagonist and methods of using same
MX2014010164A (es) 2012-02-22 2014-11-25 Alethia Biotherapeutics Inc Co-uso de un inhibidor de clusterina con un inhibidor de egfr para tratar cancer.
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
WO2014079957A1 (de) * 2012-11-23 2014-05-30 Bayer Cropscience Ag Selektive inhibition der ethylensignaltransduktion
WO2014109519A1 (ko) * 2013-01-10 2014-07-17 강원대학교산학협력단 작은안구증-연관 전사인자 유래의 펩타이드 및 이를 포함하는 조성물
US10047133B2 (en) 2014-01-22 2018-08-14 Antagonis Biotherapeutics Gmbh Glycosaminoglycan-antagonising fusion proteins and methods of using same
EP4021927A1 (en) 2019-08-29 2022-07-06 Antagonis Biotherapeutics GmbH T-cell mobilizing cxcl10 mutant with increased glycosaminoglycan binding affinity
CN110791523B (zh) * 2019-12-13 2022-05-10 南京农业大学 一种棉花抗旱相关基因GhRCHY1及其应用
KR20250040765A (ko) * 2023-09-15 2025-03-25 (주)케어젠 펩타이드를 유효성분으로 하는 발모 촉진 또는 탈모증의 억제, 예방 또는 개선용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960691A (en) * 1986-09-29 1990-10-02 Abbott Laboratories Chromatographic test strip for determining ligands or receptors
US5234911A (en) * 1990-07-09 1993-08-10 Gist-Brocades, N.V. Substance with interleukin-8 inhibiting activity and process for its preparation
AU8947791A (en) 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
EP0607777B1 (de) * 1993-01-08 1998-12-09 Hoechst Aktiengesellschaft Verwendung von Leflunomid zur Hemmung von Interleukin 8
JP2694321B2 (ja) * 1993-03-10 1997-12-24 大塚製薬株式会社 インターロイキン−1阻害剤
US5527546A (en) * 1994-08-10 1996-06-18 Bayer Corporation Human interleukin 6 inhibitor
US5866402A (en) 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−8産生阻害剤
US6852696B2 (en) * 1999-03-26 2005-02-08 The University Of Texas System Inhibitors of glycosaminoglycans
ATE466069T1 (de) * 2000-09-05 2010-05-15 Biosight Ltd Peptid-konjugierte antikrebs-prodrugs
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB0110430D0 (en) * 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof
JP2003063980A (ja) * 2001-08-28 2003-03-05 Noevir Co Ltd Rantes産生阻害剤
US6982170B1 (en) * 2001-12-17 2006-01-03 Maine Medical Center Research Institute Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1
JP2003306438A (ja) * 2002-02-18 2003-10-28 Shiseido Co Ltd ケモカイン発現阻害剤
JP2003267887A (ja) * 2002-03-15 2003-09-25 Shiseido Co Ltd ケモカイン発現抑制皮膚外用剤
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1495050A1 (en) * 2002-04-10 2005-01-12 Applied Research Systems ARS Holding N.V. Novel antagonists of mcp proteins
AT412785B (de) * 2003-12-04 2005-07-25 Kungl Andreas J Dr Gag-bindungsproteine

Also Published As

Publication number Publication date
JP2012165747A (ja) 2012-09-06
ATE439376T1 (de) 2009-08-15
PL1689775T3 (pl) 2011-12-30
JP2007536906A (ja) 2007-12-20
DK1689775T3 (da) 2011-09-26
US7585937B2 (en) 2009-09-08
US20090005541A1 (en) 2009-01-01
CY1112330T1 (el) 2015-12-09
US7807413B2 (en) 2010-10-05
CY1109480T1 (el) 2014-08-13
JP2012139226A (ja) 2012-07-26
JP4980721B2 (ja) 2012-07-18
CA2546789A1 (en) 2005-06-16
US20080112926A1 (en) 2008-05-15
ES2369139T3 (es) 2011-11-25
ATA19522003A (de) 2004-12-15
KR20070001917A (ko) 2007-01-04
EP1689775B1 (en) 2011-07-06
NZ547612A (en) 2009-07-31
BRPI0416544A (pt) 2007-01-09
EP2270038A3 (en) 2011-02-23
US20110144305A1 (en) 2011-06-16
CN1890264A (zh) 2007-01-03
EP1752470A1 (en) 2007-02-14
AU2004295104A1 (en) 2005-06-16
EP1689775A1 (en) 2006-08-16
PT1689775E (pt) 2011-10-13
PT1752470E (pt) 2009-10-15
PL1752470T3 (pl) 2010-01-29
US20100331237A1 (en) 2010-12-30
SI1752470T1 (sl) 2009-12-31
EP2311866A1 (en) 2011-04-20
SI1689775T1 (sl) 2011-11-30
WO2005054285A1 (en) 2005-06-16
KR101278459B1 (ko) 2013-07-01
EP2363411A1 (en) 2011-09-07
DK1752470T3 (da) 2009-12-14
EP1752470B1 (en) 2009-08-12
SG149000A1 (en) 2009-01-29
CN1890264B (zh) 2014-01-22
KR101188785B1 (ko) 2012-10-16
AT412785B (de) 2005-07-25
AU2004295104B2 (en) 2010-07-22
EP2270038A2 (en) 2011-01-05
IL175565A0 (en) 2006-09-05
ATE515269T1 (de) 2011-07-15
DE602004022595D1 (de) 2009-09-24
KR20120063542A (ko) 2012-06-15

Similar Documents

Publication Publication Date Title
ES2330362T3 (es) Proteinas de union a gag.
Hymowitz et al. IL‐17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL‐17F, and implications for receptor binding
Graham et al. Uncoupling of stem cell inhibition from monocyte chemoattraction in MIP‐1alpha by mutagenesis of the proteoglycan binding site.
JP5462623B2 (ja) Elr−cxcケモカインの高親和性アンタゴニスト
AU2002237136B2 (en) High-affinity antagonists of ELR-CXC chemokines
EP2053060A1 (en) SDF-1-based glyocosaminoglycan antagonists and methods of using same
US7365171B2 (en) Chemokine-like factors (CKLFs) with chemotactic and hematopoietic stimulating activities
Zhao et al. Humanized forms of the CXCR1/CXCR2 antagonist, bovine CXCL8 (3–74) K11R/G31P, effectively block ELR–CXC chemokine activity and airway endotoxemia pathology
Wain et al. Rapid site-directed mutagenesis of chemokines and their purification from a bacterial expression system
CN1351613A (zh) 具有细胞趋化作用和造血刺激活性的趋化素样因子
WO2013007704A2 (en) Novel sdf-1-based glycosaminoglycan antagonist and methods of using same